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EDITORIAL REVIEW
Monoclonal antibodies and identification of glomerular antigens
The pathogenesis of immune—mediated glomerular diseases
has been in the past two decades attributed to either deposition
within the glomerulus of immune complexes (IC) formed out-
side the kidney and passively trapped within the glomerular
filter, or binding of circulating free antibodies to antigens
present or trapped within the glomerulus [1]. The first glomer-
ular antigens studied were localized to the basement membrane
(BM) and it was initially considered that the linear pattern of Ig
deposits induced by the corresponding antibodies was charac-
teristic of this mode of immune deposit formation. More re-
cently, mainly through the study of Heymann's nephritis (HN),
it has become obvious that granular deposits can be formed by
binding of free circulating antibody to an antigen already
expressed by glomerular cells but irregularly distributed [2, 3].
The development of new biochemical and histochemical tech-
niques, and the advent of monoclonal antibodies (Mab) have
allowed identification of the basement membrane antigens
involved in at least some cases of anti-glomerular BM (GBM)
nephritis. The same techniques have been used to identify other
glomerular antigens. In addition, several antigens initially iden-
tified on lymphoid cells have been localized on glomerular cells
both in human and animal species. We devote this review to an
analysis of these various groups of antigens, with particular
emphasis on those for which a role in glomerular immunopa-
thology has been established.
Basement membrane antigens
Basic studies performed over the last 15 years [4] have led to
the identification of the major components of the GBM, includ-
ing collagen types IV and V, laminin, entactin, fibronectin, and
proteoglycans. In order to identify BM antigens involved in
experimental anti-GBM nephritis, polyclonal [5—81 and more
recently monoclonal [9—13] antibodies to individual GBM con-
stituents have been produced. Some of these reagents have
been used in an attempt to reproduce the classical heterologous
phase of anti-GBM disease. Linear deposits were induced with
anti-laminin [5, 61, anti-collagen type IV [6], anti-proteoglycan
[8], and several Mab [9, 10, 13] of poorly defined specificity, but
not with anti-fibronectin [71 which localized essentially in the
mesangium. Only some of these antibodies [5, 8—10] produced a
mild increase in proteinuria, but without significant glomerular
inflammation. The only exception is a Mab produced by
Thomson et al [13] which could induce proteinuria and glomer-
ular hypercellularity for doses of 2 ig/g of kidney. In general,
the results of these in vivo experiments are difficult to analyze
since the epitope (and in some cases molecular) specificity of
the antibodies is unknown. Furthermore, induction of protein-
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uria depends on factors often not simultaneously controlled,
such as doses of antibody used, as well as ability of these
antibodies to activate effector mechanisms. In spite of their
limitations, these experimental observations did suggest that
antibodies to various GBM constituents were not equally
nephrotoxic.
A substantial number of Mab have been raised to human
[14—18] basement membranes. Anti-laminin [18] and anti-
collagen type IV [14—17] have been characterized, but in most
instances, antigenic specificity has not been established. Com-
parison of the reactivity patterns obtained with mono- or
polyclonal antisera suggested heterogeneity of BM composition
throughout the organism, but decisive progress in the area of
"nephritogenic antigens" has been achieved in studies of
human anti-GBM antibodies. Initial studies [19] showing that
glomerular eluates of anti-GBM nephritis reacted with collagen-
ase digested GBM were interpreted as indicating that the
nephritogenic antigen was localized in the non-collagenous
portion of the GBM. Two major antigenic species were discern-
ible with molecular weights (MW) of 27 and 54 kilodaltons (kD)
[3]. Recently, Wieslander, Bygren and Heinegard [20—21] con-
firmed this observation and subsequently showed [22] that the
reactive material consisted of collagenase resistant sequences
of collagen type IV with molecular weights of 26 and 58
kilodaltons (kD). Very recently, Pressey and al [23] have
produced a Mab anti-human GBM which has the same reactiv-
ity as anti-GBM eluates and reacts with fragments of similar
size.
Antigens unrelated to basement membrane material
Heymann antigen
The membranous Ig deposits characteristic of HN are tradi-
tionally induced by immunization of Lewis rats with prepara-
tions of BB proteins [24-26]. Initial studies suggested that the
deposits were related to glomerular trapping of circulating IC
formed by circulating BB related antigens and the correspond-
ing antibodies. This hypothesis was based on the observation
that GN was not induced by glomerular extracts but by BB
preparations (generally referred to as FXIA) from which a
purified fraction—RTEa5—could be isolated and shown to be
nephritogenic. Furthermore, eluates obtained from glomeruli of
rats with active RN as well as polyclonal anti-RTEa5 antisera
did not stain normal glomeruli [26].
Subsequently, the development of the passive HN model
[27—29] led to the suggestion that epimembranous deposits
could be formed without intervention of circulating IC. Indeed,
Van Damme et al [30] and Couser, Steinmuller and Stilmant
[31], using cx vivo and isolated perfused kidneys, clearly
demonstrated that anti-BB antibodies could bind to glomeruli in
the absence of circulating BB antigen, thus suggesting that IC
formation occurred in situ. However, attempts to demonstrate
the glomerular expression of BB antigens by immunohistologi-
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cal techniques were unsatisfactory. Immunofluorescence tech-
niques were generally unsuccessful, although modest glomeru-
lar binding of anti-FXIA was detected after neuraminidase
treatment. By immunoperoxidase electron microscopy (IPEM),
after staining with anti-FXIA reaction product was demon-
strated on epithelial and endothelial cells [301. In early studies
using anti-FXIA antibodies purified by affinity chromatography
[321, we were able to detect fine punctuate irregular staining of
glomerular sections, but key experiments were provided by
Neale and Wilson [331 who showed that antibodies present in
glomerular eluates of rats with active HN as well as in
heterologous anti-RTEa5 bind in vitro to glomerular sections.
Furthermore, when injected in vivo or perfused in an isolated
kidney system, eluted ig bind to glomeruli [341.
Definitive evidence to establish the role of in situ IC forma-
tion in HN required identification of the antigen moiety. Recent
studies indicate that the major—and perhaps only—antigen
involved is a 330 kD BB glycoprotein, synthesized and ex-
pressed by glomerular epithelial cells, and referred to as gp 330.
Initial identification was achieved by Kerjaschki and Farquhar
[35, 36] using Lentil Lectin affinity chromatography and gel
filtration of sodium deoxycholate (DOCA) solubilized BB. In
separate experiments, in an attempt to analyze the repertoire of
antigens common to BB and glomeruli, we have produced Mab
specific for a protein of similar MW [37—39], which in all
likelihood is identical to that reported by Kerjaschki and
Farquhar. Precipitation of gp 330 by eluates of active and
passive HN constitutes the strongest evidence implicating gp
330 in the pathogenesis of HN [36, 39, 40]. This is further
confirmed by active immunization of rats with gp 330 which
induces epimembranous lg deposits 135, 36, 401, whereas pas-
sive immunization with monoclonal [40] or polyclonal [35, 40]
antibodies induces passive HN.
Availability of Mab specific for different epitopes of gp 330
[39—41] was particularly useful to ascertain its tissue localiza-
tion and exclude cross—reactive proteins since gp 330 is closely
related to maltase, another BB protein of 300 kD MW [42].
Indirect immunofluorescence with anti-gp 330 antibodies dem-
Fig. 1. Immunoultrastructural localization of a 330 kD
antigen defined by monoclonal antibodies and expressed by
BB and glomeruli: biotinylated Mab 12 followed by
peroxydase labelled avidin. Note distribution restricted to
coated pits of glomerular epithelial cells (A) and
intermicrovillar regions of proximal convoluted tubule (B).
A, x7000; B, x1700.
onstrates binding to BB, but also to glomeruli with a very fine
and punctuate pattern [36, 39, 40]. The corresponding ultra-
structural localization is very characteristic (Fig. 1). Within
tubular cells, gp 330 is concentrated at the base of proximal
tubule microvilli, and within thick walled vesicles located
immediately beneath the BB [36, 41]. Rodman et al [43] recently
established that these areas were associated with a clathrin
coat. This distribution is at variance from that observed for
maltase which is diffusely expressed on the entire surface of
microvilli [42]. On glomerular cells, gp 330 is only detectable in
coated pits, including those localized within the insertion zone
of the podocytes to the GBM [36]. Localization of gp 330 within
organelles associated with protein synthesis indicates that it is
synthesized by glomerular and tubular cells [411. Extrarenal
localization is restricted to a few organs including epididymis,
pneumocytes type II, and the visceral yolk sac [41, 44]. In these
localizations, as in the kidney, gp 330 is essentially restricted to
the coated pits, except for pneumocytes II where it is detectable
on the entire cell surface [41].
The gp 330 antigen is only a minor constituent of BB
preparations, but it is highly immunogenic, since antibodies
were detected in all polyclonal anti-FXIA tested in our labora-
tory, as well as in all fusions performed to raise monoclonal
anti-FXIA antibodies. This observation may account for the
ease with which PHN can be induced. However, numerous
other specificities can be identified in anti-BB preparations,
particularly antibodies to a 120 kD protein which gave rise to
the largest number of Mab [391. Anti-gp 330 thus constitute in
all likelihood only a minority of antibodies present in polyclonal
anti-FXIA antisera. This observation [39], in addition to the
highly restricted glomerular distribution of gp 330, may explain
why this antigen was so difficult to identify in glomeruli.
The characterization of gp 330 raises several interesting
problems. First, it is likely that all epitopes on gp 330 are not
equally involved in the formation of immune deposits in vivo.
Reports by Kerjaschki and Farquhar [44] indicated that poly-
clonal, but not monoclonal, anti-gp 330 could induce PHN. Our
experience is different since five of six antibodies defining
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different epitopes were able to induce immune deposits in vivo
[451. The lack of binding of one Mab is not explained by
different physicochemical properties, including p1, or affinity of
the Mab, and we would thus suggest that it is related to its fine
specificity which may be directed to determinants not normally
exposed in vivo. In this respect, it may be interesting to note
that Mab produced by Kerjaschki and Farquhar [36] have been
raised against material partly denatured by the elution condi-
tions and may thus be directed with greater frequency to such
determinants, or to neodeterminants elicited during the elution
process. Second, comparison of in vivo binding of mono- and
polyclonal antibodies to gp 330 indicates that highly cross—
linked immune complexes are required for electron—dense
immune deposit formation [46]. This supports the hypothesis
[47—49] that capping and shedding of initially membrane—bound
immune complexes is relevant to subepithelial, electron—dense
immune deposit formation. Third, the potential function of gp
330 is at present unknown. Its association with clathrin [43]
suggests that it is in some way associated with receptor medi-
ated endocytosis. However, whereas clathrin is found in coated
pits of most cell types of the body and is associated with a
number of distinct receptor systems [50], gp 330 has a restricted
tissue distribution and is thus not part of the clathrin system
itself. One may hypothesize that gp 330 is associated with an as
yet undefined receptor system. A final issue of importance is the
potential expression of gp 330 in other species than rat. Survey
of polyacrylamide gels of solubilized BB suggests the existence
of such a protein in rabbit and in human BB [51, 52], but
whether or not it is expressed in glomeruli is at present
unknown. In mice, a protein similar to rat gp 330 has been
demonstrated in the BB but is not expressed by glomeruli [53].
Leukocyte associated antigens
Leukocyte associated antigens localized in the kidney can be
classified as related to the major histocompatibility (MHC)
complex or to lymphocyte differentiation antigens.
MHC class I antigens are known to be expressed on all cell
types of the body, and most studies have therefore focused on
class II antigens. In the rat, using monoclonal antibodies to
framework (that is, non-polymorphic) determinants, Schreiner
et al [541 localized Ia positive cells in the mesangium. These
cells were found to be bone marrow derived [55], and varied in
number in different pathological conditions, such as aminonu-
cleoside or anti-GBM nephritis [56]. Ia was not expressed on
endothelial cells, but was detectable on proximal tubular cells
[57, 58], mainly on their basolateral membranes. In human
kidney, by contrast, Ia is exclusively expressed on endothelium
of glomerular capillaries and efferent arterioles [59], as well as
on interlobular cortical and medullary capillaries and vasa
recta. It is generally conserved in most cases of GN except in
areas of sclerosis and necrosis [60]. Ia expression by glomerular
endothelial cells may be of particular importance in graft
rejection, which is associated with severe endothelial damage.
In addition, the role of Ia expression in autoimmune diseases
has been emphasized [62, 63]. Recent experiments indicating
that Ia expression is inducible by various stimuli [61] confer
additional relevance to these findings.
Thy 1 was the first leukocyte differentiation antigen to be
identified in the mouse [64], and subsequently in other species
[65, 66]. Initially thought to be present only on T derived
lymphocytes and nervous tissues [64], the antigen was also
found on B lymphocytes as well as in several other tissues
[65—68]. Very recently, Paul et al [69] reported that in rat
kidney, Thy 1 was expressed by glomerular mesangial cells and
was detectable within mesangial matrix. Because the anti-Thy 1
antibodies used did not bind macrophages or dendritic cells, it
is conceivable that Thy 1 negative cells are the marrow-derived
Ia positive cells described above.
In human kidney [70], thymic antigens have been studied
using a variety of monoclonal antibodies to surface antigens,
including TA I (monocytes and T cells), OKT3 (mature
thymocytes), OKT4 (common and mature thymocytes and
helper/inducer T cells), OKT8 (common and mature thymo-
cytes and suppressor/cytotoxic T cells), OKT6 (common thy-
mocytes), OKT1O (early, common and mature thymocytes and
activated T and B lymphocytes). Reactivity was not found with
glomerular, tubular, or vascular structures of adult or fetal
kidney.
In contrast, B cell markers have been clearly identified [70].
The presence of C3b receptor activity on human glomerular
epithelial cells was initially reported by Gelfand, Frank and
Green [71]. Subsequently, isolation of CR1 from erythrocyte
membranes and the development of specific antisera led to
immunochemical demonstration of the receptor on glomerular
epithelial cells 172]. Additional antigens carried by B cells have
been studied by Platt, LeBien and Michael [70] using various
Mab. BA-i, which identifies a cell surface antigen expressed by
normal and malignant B cells at various stages of differentiation
and by granulocytes, reacted with parietal and visceral glomer-
ular epithelial cells of the early glomerulus (vesicle and S body
stage), but only with the parietal epithelial cells of the mature
glomerulus. BA-2, a monoclonal antibody known to react with
most acute lymphoblastic leukemia and numerous human tu-
mors of epithelial and neural crest origin, reacted in the later
stages of glomerular development (S body after capillary inva-
sion) with parietal and, to a lesser extent, visceral epithelial
cells. The most striking observations were made with BA-3 and
J5, two Mab specific for the common acute lymphoblastic
leukemia antigen (CALLA) [70, 73]. Intense staining of the
visceral epithelial cells of the most mature fetal and human
glomeruli was observed. Using simultaneous staining with
anti-GBM applied to fetal cortex, CALLA was only detectable
on cells closely associated with GBM. It was not detected
before GBM formation. In addition, the two Mab reacted with
the BB of proximal tubular cells, whereas endothelium and
GBM were consistently negative. Comparative immunoprecip-
itation analysis of radiolabeled leukemia cell membranes and
BB showed that J5 precipitated from the two preparations a
protein of very similar MW close to 95 kD [Si, 73]. The
observation that glomerular epithelial and lymphoid cells share
several differentiation antigens is intriguing. Based on previous
studies on lower vertebrates, Platt, LeBien and Michael [70]
suggested that lymphoid cells or their progenitors could share
unrecognized functions or ontogenic experiences with renal
cells, but this remains to be determined. Furthermore, the
potential role of this type of antigen in immunopathology is at
present unknown in man but is suggested by studies in experi-
mental animals.
There is at present information in animal models suggesting
that common antigens are expressed by glomerular epithelial
-I
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Fig. 2. Immuno-ultrosiructural localization of a 90 kD antigen
defined by rnonoclonal antibodies and expressed by BB and
glomeruli: biotinylated Mab 8 followed by peroxydase labelled
avidin. Note diffuse distribution on glomerular epithelial and
endothelial cell surfaces (A) and over apical microvilli of
proximal tubule (B). A, x8800; B, x 6100.
and lymphoid cells. In the process of producing antibodies
reactive with rat BB and glomeruli, we have selected a Mab
specific for a 90 kD BB protein which gives an intense fluores-
cence of BB and glomerular capillary wall [74]. This antigen is
synthesized by epithelial glomerular and proximal tubular cells
[41], and diffusely expressed on the BB and podocyte mem-
branes, and to some extent assumes a contrasting distribution
with gp 330 (Fig. 2). Moreover, its renal localization is not
restricted to epithelial structures since it is detected on
endothelial cells lining the glomerular capillary wall [53]. Ex-
trarenal localization [74—76] includes transport epithelia such as
gut, biliary pole of hepatocytes, all endothelia lining capillaries
so far studied [75], and the vast majority of normal lymphocytes
[76]. The fact that a protein of 90 kD MW can be precipitated
from radiolabeled lymphocyte membrane preparation by the
Mab practically excludes expression of distinct cross—reactive
proteins. The function of gp 90 is unknown. Its widespread
distribution in a number of transport epithelia, capillary
endothelia, and lymphocytes suggest that it may be associated
with enhanced constitutive endocytosis, unrelated to receptor
interaction [77].
The most striking observation is the ability of the correspond-
ing mono- or polyclonal antibodies to induce transient glomer-
ular deposits detectable by immunofluorescence or quantitative
paired label techniques: maximum at four hours after injection,
they are barely detectable 24 hrs after [741. The comparative
kinetics observed with a Mab to the 90 kD antigen and a Mab to
MAB 8 gp 330 are illustrated in Figure 3.
As discussed above [35, 40], present evidence suggests that
gp 90 is not necessary to induce HN, but an ancillary role may
be considered, although we have been unable to demonstrate
that glomerular eluates precipitated substantial amounts of gp
90. These results may be explained by the rapid turnover of the
immune deposits or by quenching of the antibody as it is eluted
by the large amounts of glomerular antigens, and thus do not
exclude a role of gp 90 in HN. We would, however, suggest that
this role is probably limited mainly because of the poor im-
munogenicity of gp 90 demonstrated by conventional immuni-
zation with FXIA (most antisera do not stain glomeruli) and the
low number of hybrids obtained [39]. The potential role of
antibodies to gp 90 could be related to their interaction with
endothelial or/and epithelial cells, Jeraj et al [78] have recently
demonstrated that in classical PHN some antibodies reacted
very early after injection with an antigen expressed by
endothelial cells, which subsequently became undetectable.
This antigen antibody interaction may increase glomerular
permeability to antibodies reactive with epithelial cells, such as
anti-gp 330, and may also be a source of immune complexes
migrating through the BM to the subepithelial space. The
distribution of gp 90 and the rapid turnover of the deposits
suggest that it may well account for these observations. Anti-gp
90 could also have a pathogenic role via their interactions with
1.
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Fig. 3. Comparative binding kinetics of monoclonal antibodies di-
rected against a 90 kD antigen (Mab 8, 0) or a 330 kD antigen (Mob 12,
•). The amount of radiolabeled antibody specifically bound by renal
tissue, estimated by paired label technique as % of injected dose, is
given on the ordinate as a function of time on the abscissa.
1 4 24 48 72
Time, hours
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epithelial cells. However, high doses of Mab anti-gp 90 injected
in vivo can induce definite glomerular lesions [79] characterized
by fusion of podocytes, a finding previously reported by
Mendrick, Cotran and Rennke [801 for a Mab reactive with an
antigen of different molecular wt (110 kD) but similar distribu-
tion. When considering glomerular deposits of anti-gp 90, it
should be noted that the large amounts of gp 90 expressed in the
rat in extrarenal endothelia may obscure a potentially nephrit-
ogenic effect of the anti-gp 90 antibodies, or, as suggested by
others [47—49], lead to shedding in the blood stream of immune
complexes initially formed on endothelial cells.
These observations led us to search for other models inde-
pendent of classical RN in which similar antigens might play a
pathogenetic role. Assmann et al [81] reported a model of
membranous GN induced in the mouse by passive immuniza-
tion with rabbit anti-mouse FXIA digested by pronase
(antiTAPron). The kinetics of the heterologous phase are sim-
ilar to those described in the rat with Mab anti-gp 90, but the
amount of antibody remaining in the glomeruli is sufficient to
induce the development of an autologous phase. Immuno-
precipitation analysis with antiTAPron antisera of radiolabeled
rat or mouse BB demonstrates that they contain antibodies to
the 330 and 90 kD proteins described above, but the mouse
expresses only the 90 kD antigen on its glomerular endo- and
epithelial cells, whereas the two proteins are detected in rat
glomeruli [53]. In addition, gp 90 is also expressed by mouse
thymocytes. This model thus confirms that the type of transient
immune deposits induced in the rat by Mab anti-gp 90 can be
observed with polyclonal antisera, as well as in another species.
However, endothelial expression of murine gp 90 led us to
screen Mab anti-rabbit BB [821. Two different antibodies
against BB proteins of 90 and 100 kD were found to bind
intensely to rabbit glomeruli. IPEM demonstrated that the
antigens were only expressed on epithelial cells. When studied
in vivo, the Mab were found to induce deposits with transient
kinetics, almost superimposable to those described in the rat.
These results thus indicate that antigens shared by glomerular
epithelial cells and lymphocytes may be found in several
species. It is interesting to note that the MW of CALLA (95kD)
[73] is within the range of the antigens described in the
experimental models mentioned. Furthermore, these antigens
may serve as targets for in situ formation of immune deposits,
characterized by their transient kinetics. These observations
may constitute a model for short—lived membranous GN such
as those induced by drugs.
Other antigens expressed by glomerular cells
The antigens described above have been identified because of
their simultaneous expression on BB and hematopoietic cells.
Several groups have attempted to characterize directly constit-
uents of epithelial cells. As expected, using Mab production,
antigens common to BB and glomeruli have been found [83—85],
but an antibody specific for glomerular epithelial cells has also
been described [84]. In most instances, however, characteriza-
tion of the corresponding antigens has not been achieved. Using
biochemical techniques, Kerjaschki, Sharkey and Farquhar
have isolated a protein that they termed podocalyxin [86],
which carries most of the glomerular sialic acid. The signifi-
cance of this protein is suggested by the fact that it decreases in
various glomerWar diseases, such as aminonucleoside nephritis
[871. Very recently, podoendin, a new 62 kD cell surface protein
of the podocyte and endothelium has been reported [881. Work
in this area is only beginning and further studies will provide
useful information on the function and immunopathology of the
glomerular capillary wall.
In conclusion, this paper presents recent advances of our
knowledge of antigens expressed by glomeruli, brought about
by the development of new biochemical and immunochemical
techniques. Mab production coupled to antigen identification
have been particularly useful. Characterization of several of the
BM antigens involved in anti-GBM disease has been achieved.
In the area of antigens unrelated to BM, the antigen responsible
for RN has been isolated. Independent studies have established
the presence in animals and man of antigens expressed by BB
and glomeruli and shared by hematopoietic cells. The signifi-
cance of this simultaneous common expression is unknown.
Finally, identification of glomerular epithelial antigens by Mab
provides a unique opportunity to study immunopathological
models in which the antigen—antibody system is very precisely
defined. This approach has already been fruitful since it has
been shown that the kinetics of antibody deposits in glomeruli
due to in situ IC formation varied considerably with the antigen
involved. It could be also very valuable for studies devoted to
the role of physico-chemical properties of antibodies in the in
situ formation of immune deposits, a point which has yet been
investigated only with polyclonal antibodies.
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